TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Alumis Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Inc., a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 17.65 million shares at $17.00 per share, generating approximately $300 million in gross proceeds. The offering is expected to close on January 9, 2026, with underwriters granted a 30-day option to purchase an additional 2.65 million shares. Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are serving as joint book-running managers.

Insights
ALMS   positive

The company successfully priced an upsized public offering at $17.00 per share, raising $300 million to fund its clinical-stage drug development pipeline. The upsizing of the offering and strong pricing indicate investor confidence in the company's therapeutic candidates, particularly its lead program envudeucitinib for immune-mediated diseases.